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Abstract
Introduction Use of fluorescence imaging in oncology is evolving
rapidly, and nontargeted fluorochromes are currently being
investigated for clinical application. Here, we investigated
whether the degree of tumour angiogenesis can be assessed in
vivo by planar and tomographic methods using the perfusion-type
cyanine dye SIDAG (1,1'-bis- [4-sulfobutyl]indotricarbocyanine-
5,5'-dicarboxylic acid diglucamide monosodium).
Method Mice were xenografted with moderately (MCF7,
DU4475) or highly vascularized (HT1080, MDA-MB435)
tumours and scanned up to 24 hours after intravenous SIDAG
injection using fluorescence reflectance imaging. Contrast-to-
noise ratio was calculated for all tumours, and fluorochrome
accumulation was quantified using fluorescence-mediated
tomography. The vascular volume fraction of the xenografts,
serving as a surrogate marker for angiogenesis, was measured
using magnetic resonance imaging, and blood vessel profile
(BVP) density and vascular endothelial growth factor expression
were determined.
Results SIDAG accumulation correlated well with angiogenic
burden, with maximum contrast to noise ratio for MDA-MB435
(P  < 0.0001), followed by HT1080, MCF7 and DU4475
tumours. Fluorescence-mediated tomography revealed 4.6-fold
higher fluorochrome concentrations in MDA-MB435 than in
DU4475 tumours (229 ± 90 nmol/l versus 49 ± 22 nmol/l; P <
0.05). The vascular volume fraction was 4.5-fold (3.58 ± 0.9%
versus 0.8 ± 0.53%; P < 0.01), blood vessel profile density 5-
fold (399 ± 36 BVPs/mm2 versus 78 ± 16 BVPs/mm2) and
vascular endothelial growth factor expression 4-fold higher for
MDA-MB435 than for DU4475 tumours.
Conclusion Our data suggest that perfusion-type cyanine dyes
allow assessment of angiogenesis in vivo using planar or
tomographic imaging technology. They may thus facilitate
characterization of solid tumours.
Introduction
Contrast-enhanced optical imaging is an emerging modality
that may be used to detect and characterize solid tumours
such as breast cancer [1,2]. Optical techniques based on
intrinsic optical contrast (such as diffuse optical tomography)
can provide spectroscopic information about physiological
and functional tissue parameters (for instance, tissue oxygen-
ation) [3,4]. However, there have been several unsuccessful
attempts to demonstrate that nonenhanced optical mammog-
raphy has diagnostic utility [5]. More recently, substantial effort
has been invested in the development of fluorescent probes,
which potentially can increase cancer to noncancer tissue
contrast and therefore improve sensitivity and specificity of
breast cancer imaging [4,6]. Indeed, indocyanine green (ICG)-
enhanced diffuse optical mammography was successfully
applied to detection of breast lesions in a proof-of-concept
study [7]. However, factors such as rapid uptake by liver tis-
sue, small quantum yield and low stability in watery solutions
BVP = blood vessel profile; BVPD = blood vessel profile density; CNBR = contrast-to-noise ratio; FMT = fluorescence mediated tomography; FRI = 
fluorescence reflectance imaging; MRI = magnetic resonance imaging; ICG = indocyanine green; ROI = region of interest; SIDAG = 1,1'-bis-(4-sul-
fobutyl)indotricarbocyanine-5,5'-dicarboxylic acid diglucamide monosodium; VEGF = vascular endothelial growth factor; VVF = vascular volume 
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render ICG unsuitable as an optical contrast agent for detec-
tion of breast tumours [8].
Hence, other cyanine-based contrast agents have recently
been developed that possess more favourable optical and
pharmacokinetic properties. SIDAG (1,1'-bis- [4-sul-
fobutyl]indotricarbocyanine-5,5'-dicarboxylic acid diglucamide
monosodium; Global Drug Discovery, Bayer Schering Pharma
AG, Berlin, Germany) is among these recently synthesized
derivatives of ICG that have improved photophysical and phar-
macological characteristics (Figure 1) [8,9]. Based on recent
developments in optical imaging, it is conceivable that the first
clinically applied fluorochromes will be perfusion-type (nontar-
geted) contrast agents. However, it is currently unclear
whether nontargeted, low-molecular-weight fluorochromes
that are currently on the verge of being clinically introduced
will allow us to extrapolate surrogate markers of tumour angio-
genesis using planar or tomographic optical imaging. The aim
of the present study was to explore the potential of SIDAG in
differentiating the angiogenic burden associated with various
cancer xenografts.
Materials and methods
Fluorochrome
The synthesis and physicochemical characteristics of SIDAG
are described in detail elsewhere [9-11]. Compared with ICG,
SIDAG exhibits improved hydrophilicity and lower plasma pro-
tein binding, with a free fraction of the fluorochrome of approx-
imately 40% (ICG has 95% to 100% plasma protein binding).
The excitation peak of the fluorochrome is 753 nm in phos-
phate-buffered saline and 755 nm in plasma, while the emis-
sion peak is around 790 nm for both media. A detailed
description of the properties of SIDAG can be found else-
where [9-12].
Cell culture and tumour models
All primary cell lines (HT1080 fibrosarcoma, MCF7 breast
adenocarcinoma, MDA-MB435 melanoma and DU4475 ade-
nocarcinoma) used in this study were obtained from the Amer-
ican Tissue Culture Collection (Manassas, VA, USA). All cell
lines were cultured in modified Eagle's medium, RPMI-1640,
or Dulbecco's modified Eagle's medium cell media supple-
mented with 10% foetal calf serum and 1% penicillin/strepto-
mycin (all products from Invitrogen Corporation, San Diego,
CA, USA). Cells were grown using routine procedures in a
monolayer culture at 37°C in a 5% carbon dioxide humidified
atmosphere. To grow and propagate the tumours in mice, 2 ×
106 cells were injected into the mouse flank (nu/nu; Charles
Rivers, Sulzfeld, Germany). In the preliminary set of experi-
ments at the beginning of the project, the pharmacokinetic
properties of the fluorochrome and the optimal time window
for animal scanning had to be determined. For this purpose,
four animals bearing MDA-MB435 tumours were scanned
repetitively up to 72 hours after probe injection (30 minutes,
and 1, 2, 3, 6, 12, 24, 48 and 72 hours). Based on these data,
all other animals were scanned 3, 6 and 24 hours after injec-
tion. Because MCF7 cells are hormone dependent, an oestra-
diol pellet (0.72 mg/pellet; Innovative Research of America,
Sarasota, USA) was implanted subcutaneously 1 week before
tumour inoculation. All tumours were allowed to grow to
approximately 5 to 7 mm in diameter before imaging studies
were performed. In order to assess whether fluorochrome
accumulation in different xenografts can reliably be distin-
guished even in the same individuals, five animals were co-
implanted with both MDA-MB435 and DU4475 tumours. A
total of 43 tumours were examined and evaluated in this study.
In vivo optical imaging studies
For reflectance and tomographic imaging studies, the mice
were anaesthetized by intraperitoneal administration of keta-
mine (125 mg/kg body weight) and xylazine (12.5 mg/kg body
weight). The average time of anesthesia was approximately 20
to 30 minutes and animals were allowed to wake up between
imaging sessions. Before injection of the contrast agent, an
anatomical white light image was obtained. SIDAG was dis-
solved in saline to achieve a 0.2 mmol/l solution and injected
into the tail vein at a dose of 2 μmol/kg body weight. All exper-
iments were performed with approval of the Institutional Ani-
mal Care Committee.
Fluorescence reflectance imaging
The whole body multichannel small animal imager is a proto-
type reflectance imager and has been described elsewhere
[13] (BonSAI – prototype imager; Siemens Medical Solutions,
Erlangen, Germany). The acquisition time for near-infrared flu-
orescence images was 1 second at maximum photon flux of
the system. Images were acquired using a charged-coupled
device camera sensitive to near infrared light (Hamamatsu
Photonics, Hamamatsu – City, Japan) and processed on a PC-
based system. For signal quantification, the contrast-to-noise
ratio was determined by region of interest (ROI) analysis
(about 900 pixels) in the region of the tumour. ROIs of the
same size were placed in nontarget tissue (hip muscle) and in
the background beside the mouse. The contrast-to-noise ratio
(CNR) was calculated as CNR = (SItumour – SImuscle)/SDnoise
(where SItumour is the signal intensity of the tumour, SImuscle is
Figure 1
SIDAG SIDAG. Presented is the chemical structure of SIDAG (1,1'-bis- [4-sul-
fobutyl]indotricarbocyanine-5,5'-dicarboxylic acid diglucamide 
monosodium).Available online http://breast-cancer-research.com/content/10/2/R23
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the signal intensity of the muscle and SDnoise is the standard
deviation of background).
Fluorescence mediated tomography
All tomographic optical imaging studies were performed by a
small-animal fluorescence mediated tomography (FMT) sys-
tem (VisEn FMT™; VisEn Medical Inc., Woburn, MA, USA),
which has been described in detail elsewhere [14]. FMT imag-
ing was conducted 24 hours after injection of SIDAG immedi-
ately after the last fluorescence reflectance imaging (FRI) scan
in a subset of animals (n = 4 for MDA-MB435 and DU4475, n
= 5 for HT1080 and n = 6 for MCF7). Animal scan times
ranged from 2 to 5 minutes; tomographic reconstruction times
were approximately 1 to 3 minutes. The fluorochrome concen-
tration inside the tumour tissue was measured using volume of
interest analysis. Briefly, images were displayed as raw and as
reconstructed three-dimensional datasets in transverse, sagit-
tal and coronal planes. The target volume was defined by ROI
placement in all three reconstructed planes.
Fluorochrome concentration in the target tissue was then
automatically calculated from the reconstructed images.
Magnetic resonance imaging and determination of 
vascular volume fraction
Magnetic resonance imaging (MRI) was performed using a
clinical 3 Tesla magnetic resonance system (Intera; Philips
Medical Systems, Best, The Netherlands) using a custom-
made solenoid coil for animal imaging with a diameter of 70
mm (Philips Medical Systems, Philips, Hamburg, Germany).
Tumour-bearing animals (n = 4 for each xenograft) were cho-
sen randomly from the each group and were anaesthetized by
intraperitoneal injection of ketamine (125 mg/kg body weight)
and xylazine (12.5 mg/kg body weight). For stable vascular
access, a jugular vein catheter (SIMS Portex, Kent, UK) was
inserted [15]. Vascular volume fraction (VVF) measurements
were performed as described elsewhere [16]. In our study the
magnetic resonance relaxation time T2* and the R2* relaxation
rate (1/T2*), respectively, were measured before and after
intravenous injection of ultrasmall superparamagnetic iron
oxide crystals (80 μmol Fe/kg body weight; SHU 555 C; Bayer
Schering Pharma AG, Berlin, Germany) using a multiecho
sequence with the following parameters: repetition time 474
ms, echo time 32 ms, Δecho time 5.8 ms, 11 echoes, slice
thickness 1 mm, field of view 50 × 50 mm, matrix 192 × 192
(reconstructed 256 × 256), voxel size 0.2 × 0.2 × 1.0 mm, and
total scan duration 75 seconds for four slices. ΔR2* maps
were calculated and quantitative ΔR2* data were measured in
ROIs covering the whole tumour volume. The VVF was calcu-
lated by calibrating the ΔR2* of the tumour with the corre-
sponding ΔR2* of muscle tissue, which has an average VVF of
1.89% [17].
Immunhistochemistry and calculation of blood vessel 
profile density
Six samples from each tumour type were chosen randomly and
prepared, and each was embedded and snap frozen at -70°C
immediately after imaging. For each tumour sample, on aver-
age 12 sections were selected using a systematic random
sampling principle, as was described by Gundersen and
Jensen [18]. Immunohistochemistry was performed on these
cryostat sections (5 μm) using a biotynilated monoclonal rat-
anti-mouse CD31 antibody (Pecam-1, MEC; BD Biosciences
Pharmingen, San Jose, CA, USA) and the streptavidin-biotin-
peroxidase technique. The blood vessel profile density (BVPD)
was analyzed using a microscope (Axioskop 40; Zeiss, Göttin-
gen, Germany) equipped with a mechanical stage linked to a
computer running a stereological program (StereoInvestiga-
tor; MicroBrightField Inc., Williston, VT, USA). A camera
(DXC-950P, 3CCD color video camera; Sony, Atsugi, Japan)
connected to the microscope was used to transfer the micro-
scopic picture to the computer screen. After defining the ROI
and the number of desired fields of view at a magnification of
53×, the computer program defines and moves automatically
to the analysis fields and randomly projects onto them an unbi-
ased counting frame for blood vessel profile counting at a
magnification of 530×. The counting rule applied to the count-
ing tool and the evaluation of the number of profiles per area
(in this case the blood vessel profile density [BVPD]) were in
accordance with the method described by Gundersen and
coworkers [18]. The BVPD is expressed as blood vessel pro-
files (BVPs)/mm2 (BVP/mm2).
Western blotting
Secreted vascular endothelial growth factor (VEGF) was ana-
lyzed in the supernatant of cultivated tumour cells that had
been maintained in serum-free medium for 24 to 48 hours
[19]. The supernatant from each cell line (equivalent to 1 × 107
cells) was collected and purified by centrifugation (1,500 g at
4°C for 10 minutes and 10,000 g at 4°C for 30 minutes). To
precipitate and thus concentrate the protein, a twofold volume
of cold acetone was added to each sample and maintained at
-20°C for 16 hours, followed by centrifugation at 10,000 g at
4°C for 30 minutes. The protein pellets were dissolved in 100
μl of 6× SDS sample buffer (New England Biolabs, Beverley,
MA, USA). Proteins were then electrophoretically separated in
nonreducing 12% SDS-PAGE and transferred to polyvinyli-
dene fluoride membranes (Millipore Corporation, Bedford,
MA, USA). After blocking, immunoblots were incubated with
VEGF polyclonal antibody (VEGF A-20: sc-152; Santa Cruz
Biotechnology, Santa Cruz, CA, USA) and then with a peroxi-
dase-conjugated goat anti-rabbit IgG secondary antibody
(Sigma, St. Louis, MO, USA). Peroxidase activity was revealed
using ECL chemiluminescence (Amersham Bioschiences, Pis-
cataway, NJ, USA) and X-ray film, as described by the manu-
facturers. Recombinant human VEGF165  (Oncogene,
Cambridge, MA, USA) was used as a positive control. The
developed films were scanned in an AlphaImager 2200 (AlphaBreast Cancer Research    Vol 10 No 2    Wall et al.
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Innotech Corp., San Leandro, CA, USA) and the amount of
protein was quantified using the provided Alpha Ease FC soft-
ware (version 3.2.1). For comparison, the VEGF protein
expression level in MDA-MB435 cells was set at 100%, and
all other cell types were scaled accordingly.
Statistical analysis
Data are presented as mean ± standard deviation. Differences
between the tumour xenografts (CNR, SIDAG concentration
and VVF) were statistically evaluated by analysis of variance
with Bonferroni correction for multiple comparisons. P < 0.05
was regarded to indicate statistically significant differences.
Results
Near-infrared reflectance imaging
Sequential FRI during the first 90 minutes after intravenous
administration of contrast agent yielded moderate CNRs in the
tumour tissue, even in highly vascularized tumours such as
MDA-MB435 xenografts (Figure 2). The tumours began to
become discernible approximately 2 hours after injection, and
maximal CNRs were observed 3 hours after injection. The flu-
orescence signal then slowly faded within the following 72
hours. Based on these results, the subsequent FRI and FMT
experiments were performed 3, 6 and 24 hours after injection
of SIDAG (Figure 3).
The results of all measurements are summarized in Table 1. In
the FRI experiments, all xenografts were visible on FRI images
at 3, 6 and 24 hours after injection. However, on comparing
the different tumour types, MDA-MB435 melanomas exhibited
the highest CNR at each time point, followed by the HT1080
fibrosarcomas, and the MCF7 and the DU4475 adenocarcino-
mas (P < 0.0001; Figure 3). Over time the CNR declined sig-
nificantly while the signal differences among the various
tumour types was unchanged (MDA-MB435 continued to
exhibit the highest fluoresence signal intensity and DU4475
tumour xenograft the lowest; Figure 3).
Co-implantation experiments with mice bearing both the highly
vascularized MDA-MB435 and poorly vascularized DU4475
tumours (n = 5) confirmed the previous FRI findings and
allowed clear differentiation of MDA-MB435 melanomas from
DU4475 adenocarcinomas within the same animal (Figure 4).
Specifically, 3 hours after injection of SIDAG the CNR in the
MDA-MB tumours was 553 ± 91 versus 195 ± 36 in DU4475
tumours (6 hours after injection: 508 ± 119 versus 167 ± 51;
24 hours after injection: 363 ± 84 versus 105 ± 20).
Fluorescence mediated tomography
In order to assess the distribution profile and the concentration
of SIDAG in deeper tissue sections more thoroughly, correla-
tive FMT imaging was performed 24 hours after injection of the
fluorochrome (Figure 4). FMT revealed an inhomogenous dis-
tribution of fluorochrome within the tumour volume (Figure 4).
Double implanted tumour xenografts clearly differed in
fluorochrome accumulation and were thus easily distinguisha-
ble by FRI and FMT (Figure 4). Maximum fluorochrome con-
centrations were found in the MDA-MB435 tumours (229 ±
90 nmol/l) whereas the fluorochrome accumulation in the
other tumour types was significantly lower (HT1080: 92 ± 65
nmol/l; MCF7: 65 ± 50 nmol/l; DU4475: 49 ± 22 nmol/l; P <
0.05; Figure 4).
Vascular volume fraction by magnetic resonance 
imaging
The independent in vivo MRI measurements showed an
approximately 4.5-fold higher vascular volume fraction (VVF) in
tumour tissue for MDA-MB435 (3.58 ± 0.9%) than for
DU4475 (0.8 ± 0.53%; P < 0.01; Table 1). Likewise, the VVF
for HT1080 (1.9 ± 0.67%; P < 0.05) and MCF7 (0.75 ±
0.52%; P < 0.01) were also significantly lower than for MDA-
MB435 xenografts.
Blood vessel profile density and VEGF expression
The density of the blood vessel profiles per area was highest
in MDA-MB435 tumours (399 ± 36 BVPs/mm2), followed by
the HT1080 tumours (128 ± 38 BVPs/mm2). A much lower
BVPD was measured in the DU4475 (78 ± 16 BVPs/mm2)
Figure 2
Contrast enhancement of a highly vascularized melanoma (MDA- MB435) Contrast enhancement of a highly vascularized melanoma (MDA-
MB435). (a) Fluorescence reflectance images were repetitively 
acquired up to 24 hours after injection of SIDAG (2 μmol/kg body 
weight). Note the strong enhancement of the tumour nodule, becoming 
increasingly conspicuous over the first 3 hours. Shown is a white light 
image, and fluorescence reflectance imaging images at 30, 60, 120 
and 180 minutes after injection. (b) Quantitative data analysis revealed 
a rapid increase in the contrast to noise ratio (CNR) over the first 3 
hours followed by a gradual wash out of the fluorochrome from the 
tumour tissue.Available online http://breast-cancer-research.com/content/10/2/R23
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and MCF7 tumours (59 ± 10 BVPs/mm2; Figure 5 and Table
1). The highest expression of VEGF was found for MDA-
MB435 tumour cells (100%), followed by HT1080 (90%),
MCF7 (71%) and DU4475 (27%).
Discussion
Optical imaging may provide ideal tools for noninvasive imag-
ing of solid tumours such as breast cancer. Specifically, in the
near infrared range, light can efficiently penetrate (breast) tis-
sue, facilitating noninvasive probing of tissue with respect to
oxyhaemoglobin and deoxyhaemoglobin, and fat and water
content. Moreover, experimental data suggest that optical
imaging is highly sensitive in resolving optical signatures, even
in the picomolar range, which potentially can be exploited for
molecular target detection in vivo [20].
Recent clinical data with nonenhanced diffuse optical tomog-
raphy (computed tomography laser mammography) [5] dem-
onstrated the basic feasibility of using nonenhanced optical
tomography for breast cancer imaging. However, despite
technological advances, including improved light generation,
better detector systems and rigorous mathematical modelling,
the findings of the present study corroborate previous reports
Figure 3
FRI of different tumour xenografts over time FRI of different tumour xenografts over time. (a) White light images of different tumour xenografts (as indicated), followed by fluorescence reflect-
ance imaging (FRI) images taken sequentially after application of 2 μmol/kg body weight SIDAG. Note the strong fluorescence signal in the HT1080 
(n = 11) fibrosarcomas and in the MDA-MB435 (n = 10) melanomas, whereas the MCF7 (n = 9) and DU4475 (n = 13) adenocarcinomas exhibit 
only moderate tumour fluorescence. (b) Quantitative data analysis revealed significantly higher contrast to noise ratios (CNRs) for the HT180 and 
MDA-MB435 xenografts compared with the MCF7 and the DU4475 tumours.Breast Cancer Research    Vol 10 No 2    Wall et al.
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[21-23] that found that nonenhanced optical mammography
had limited sensitivity and specificity.
However, there is a good body of evidence that combining
novel optical imaging technologies with fluorochrome-based
optical contrast agents may markedly improve the sensitivity of
the method, depending on fluorescent probe employed. In this
regard, 'target-specific' or 'smart' fluorochromes can sensi-
tively detect specific tumour epitopes, resolving structures
even at picomolar concentrations, similar to scintigraphic
imaging techniques.
Although target-specific and 'smart' fluorochromes can be
applied to resolve molecular targets in vivo, the first clinical
studies are currently being performed using non-target-spe-
cific, 'perfusion-type' fluorochromes, which are comparable to
other clinically applied nonspecific contrast agents (for
instance, gadolinum-based magnetic resonance or iodine-
based radiographic contrast agents) [7]. It remains unclear
whether these nonspecific fluorophores may be helpful in
extrapolating relevant tissue parameters such as tissue per-
fusion, or whether they may even provide surrogate markers
for tumour angiogenesis as an example.
The purpose of this study was therefore to apply SIDAG, a
new generation, 'perfusion-type' fluorochrome, for two-dimen-
sional and three-dimensional optical imaging in human cancer
xenografts that significantly differ in their degree of tumour
angiogenesis.
Our data reveal significant differences in tumour vasculariza-
tion of the xenografts, as measured in vivo by iron oxide
enhanced MRI as well as ex vivo by the BVPD and the level of
VEGF expression as surrogate parameters of tumour angio-
genesis. Planar and tomographic optical imaging revealed that
retention of the fluorochrome in tumour xenografts made
lesions clearly apparent. Interestingly, the retained fluoro-
chrome concentration significantly increases with the degree
Table 1
Summary of results for all tumour xenografts
Tumour model CNR calculated by FRI (AU)a FMT (nmol/l) VVF (%)b BVPD (BVPs/mm2)
MDA-MB435: melanoma 389 ± 72 (n = 10) 229 ± 90 (n = 4) 3.58 ± 0.9 (n = 4) 399 ± 36 (n = 6)
HT1080: fibrosarcoma 232 ± 99 (n = 11) 92 ± 65 (n = 5) 1.9 ± 0.7 (n = 4) 128 ± 38 (n = 6)
MCF7: adenocarcinoma 185 ± 57 (n = 9) 65 ± 50 (n = 6) 0.75 ± 0.5 (n = 4) 59 ± 10 (n = 6)
DU4475: adenocarcinoma 167 ± 79 (n = 13) 49 ± 22 (n = 4) 0.8 ± 0.5 (n = 4) 78 ± 16 (n = 6)
Data are expressed as mean ± standard deviation. Note that the data generated by fluorescence imaging technologies (FRI, FMT) correlate well 
with in in vivo (VVF) and ex vivo (BVDP) surrogate markers of tumour angiogenesis. aCalculated 24 hours after intravenous injection of SIDAG. 
bMeasured using magnetic resonance imaging. AU, arbitrary units; BVP, blood vessel profile; BVPD: blood vessel profiles density; FMT, 
fluorescence-mediated tomography; FRI, fluorescence reflectance imaging; VVF, vascular volume fraction.
Figure 4
Quantification of fluorochrome accumulation in a double xenografted mouse by FMT Quantification of fluorochrome accumulation in a double xenografted mouse by FMT. (a-c) Fluorescence-mediated tomography (FMT) was per-
formed 24 hours after injection of SIDAG in order to resolve the three-dimensional fluorochrome distribution and for quantification of fluorochrome 
concentration in the target tissue: panel a shows a white light image, panel b shows colour-coded FMT data for MDA-MB435, and panel c shows 
the DU4475 xenograft superimposed on white light images. The average fluorochrome concentration in the MDA-MB xenografts ranged around 229 
± 90 nmol/l, whereas DU4475 exhibited significantly lesser fluorochrome accumulation (49 ± 22 nmol/l; P < 0.01).Available online http://breast-cancer-research.com/content/10/2/R23
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of tumour angiogenesis, and both FMT and FRI data correlate
with the VVF, BVPD and VEGF level. The data from this study
therefore support the hypothesis that tumour-induced angio-
genesis can indeed be noninvasively evaluated using a non-
specific, perfusion-type fluorochrome and appropriate imaging
technology.
The first clinical feasibility study examining ICG-enhanced dif-
fuse optical mammography was that presented by
Ntziachristos and coworkers [7]. Those investigators exam-
ined patients with various breast lesions using ICG-enhanced
diffuse optical mammography (off-label use) concurrently with
contrast-enhanced MRI, and they demonstrated that it is
indeed possible to resolve accumulation of ICG using diffuse
optical tomographic methods and that ICG accumulation cor-
relates with gadolinum-based signal enhancement in MRI [7].
The use of ICG in breast imaging is restricted by many factors.
Because of a propensity to bind to albumin (95%), ICG distrib-
utes predominantly in the vascular space and undergoes rapid
uptake by the liver. The plasma level of ICG falls within minutes
after intravenous administration, which shortens the period
during which imaging can be done [9]. Contrary to ICG,
SIDAG has low plasma protein binding (10%) with the parti-
tion coefficient under 0.005 (ICG = ∞). Consequently, the
SIDAG exhibits greater solubility and distributes in the extra-
cellular space [24]. Further important features are greater flu-
orescent yield and tolerability.
In the present study the visibility of tumour xenografts with FRI
increased substantially over the first 3 hours, showing a more
than sixfold increase in CNR. This phenomenon can be attrib-
uted to the fact that SIDAG extravasated through leaky tumour
vessels and was retained within the tumour interstitium over
the first hours, whereas nontarget structures (nontumourous
tissue) exhibited marked washout subsequently, which
resulted in an increase in CNR.
The washin and washout phenomena described above are
clearly depended on the tumour biology examined. Indeed,
xenografts with a high degree of tumour angiogenesis (MDA-
MB435 and HT1080) exhibited significantly higher SIDAG
concentrations than did the poorly vascularized adenocarcino-
mas (MCF7 and DU4475).
Generally, factors such as vessel density, capillary permeabil-
ity inside the tumours, or a combination of both may be respon-
sible for greater enhancement of tumour tissue, because the
microvascular hyperpermeability observed in carcinomas
increases with increasing tumour grade [25]. This phenome-
non is also well known from other imaging modalities such as
gadolinum-enhanced MRI. Indeed, the degree of gadolinum
extravasation and thus the signal increase is currently used as
a diagnostic tool for the detection of breast cancer by MRI.
Compared with planar imaging technology (FRI), the FMT data
more closely resembled the data generated by iron oxide
enhanced MRI, which is a well established tool for the assess-
ment of tumour angiogenesis. Although, for example, MRI
revealed an approximately 4.5-fold higher VVF for MDA-
MB435 than for DU4475 tumours, FRI revealed only a 2.3-fold
higher fluorescence signal. However, FMT resolved an approx-
imately 4.6-fold higher fluorochrome accumulation in the
MDA-MB435 tumours as compared with DU4475 adenocar-
cinomas. This may be attributed to ability to resolve and differ-
entiate deep-seated tissue fluorescence (such as that deriving
from the liver) from more superficially located tumour-associ-
ated fluorochrome accumulation. Although FRI cannot
differentiate between deep-seated strongly fluorescent
structures and superficial fluorochrome accumulation, cross-
sectional imaging with FMT can do so. Thus, scattered fluores-
cence from deep-seated structures can interfere significantly
with imaging results with FRI as compared with FMT.
Contrary to most other clinically available cross-sectional
imaging modalities, FRI and FMT allowed us to visualize the
fluorochrome in highly vascularized tumours even 24 hours
after injection with reasonable CNR. Moreover, the fluoro-
chrome was administered at a dose of only 2 μmol/kg, which
is more than two orders of magnitude lower than for
gadolinum-enhanced MRI studies. These results therefore
Figure 5
Immunhistochemistry of tumour xenografts Immunhistochemistry of tumour xenografts. (a-d) Brown precipitates 
indicate the presence of CD31, representing microvessel formation: 
panel a shows MDA-MB435 tissue, panel b HT1080, panel c MCF7, 
and panel d DU4475. Note the strong difference in tumour vasculariza-
tion. Although the MDA-MB435 and the HT1080 tumours exhibit a high 
degree of angiogenesis, the DU4475 and MCF7 tumours show a 
clearly lower amount of CD31 positive vessels (original magnification: 
100×). Analysis of blood vessel profile density (BVPD) per area for all 
tumour types using stereological tools revealed the highest BVPD to be 
in MDA-MB435 (399 ± 36 BVPs/mm2) tumours followed by the 
HT1080 tumours (128 ± 38 BVPs/mm2), whereas the other two 
tumour types exhibited lower BVPD at a comparable level (MCF7 59 ± 
10 BVPs/mm2; DU4475 78 ± 16 BVPs/mm2).Breast Cancer Research    Vol 10 No 2    Wall et al.
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underline the high sensitivity of this imaging approach as com-
pared with MRI, for example. More recent developments in the
design of optical contrast agents include targeting tumour-
specific receptors or the design of activatable 'smart' fluoro-
chromes that can further boost the CNR, given an appropriate
tracer design [26,27].
It is clear that fluorescence-enhanced optical imaging not only
has tomographic applications in breast cancer imaging but
also applications for a variety of other tumour types. Experi-
mental studies have focused on imaging dysplastic colonic
polyps, lung tumours and intracerebral malignomas [28].
Moreover, a combination with FRI applications in catheter-
based or endoscopy-based imaging systems may be practical
for a variety of other clinical scenarios [29]. Finally, real-time
intraoperative FRI systems may greatly facilitate the detection
of tumour margins and metastatic spread, such as to locore-
gional lymph nodes, and may therefore provide the surgeon
with intraoperative guidance [30,31].
The present study has a few limitations: It remains unclear
whether SIDAG-enhanced FMT/FRI can resolve subtle
changes in vascular density or tumour perfusion, caused by
antianiogenic therapy. Moreover, we did not conduct pharma-
cokinetic studies to analyze dynamically the distribution of the
fluorochrome between intravascular and extravascular com-
partments. However, these issues will be addressed in future
projects.
Conclusion
The results of the present study indicate that clinically relevant
tissue parameters such as tumour angiogenesis can reliably
be estimated using a perfusion-type optical contrast agent and
planar or tomographic optical imaging methods. These types
of agents are about to enter the clincal arena, and their use in
diffuse optical tomography of the breast may facilitate lesion
detection and characterization.
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